Basilea beginnt Phase-1/2-Studie FIDES-03 mit Derazantinib bei Patienten mit Magenkrebs

Ads

You May Also Like

FIT Biotech Oy: Chairman of the board on leave of absence

FIT Biotech Oy                                                             Company release 16.8.2018 at 04:00 PM EET Chairman of the board ...

TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval to treat complex perianal fistulas in Crohn’s disease in Europe

PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval ...